Clinical Trial Update: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on a completed Phase 1/2 study of veliparib plus topotecan in relapsed ovarian cancer patients with negative or unknown BRCA …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Topotecan (topotecan)
• Veliparib (veliparib)

Snippet

Sponsor: Vejle Hospital | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED